Adrian Rabin

Davis Polk & Wardwell advised Immedica Pharma AB on the transaction. Immedica Pharma AB announced its acquisition from Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) of all assets related...

Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...

Davis Polk advised BofA Securities, Inc., SVB Securities LLC on the offering. Cooley LLP represented Oculis Holding in the offering. Vischer AG advised Oculis Holding for...

Wilson Sonsini advised Seagate on the offering, while Davis Polk advised Morgan Stanley & Co. LLC. Seagate HDD Cayman (the “Company”), a subsidiary of Seagate Technology...

Davis Polk advised the sales agents, RBC Capital Markets, LLC and Evercore Group L.L.C., on the transaction. Emergent BioSolutions Inc., an American multinational specialty biopharmaceutical company headquartered in...

Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...

Meitar and Cooley advised Gamida Cell on the offering, and Davis Polk advised the underwriter. Gamida Cell Ltd. announced the $23 million SEC-registered follow-on offering of...

K&L Gates advised AVITA, and Davis Polk advised the sales agent for the offering. AVITA Medical, Inc. announced the establishment of an SEC-registered at-the-market program of...

Wilmer Cutler, DLA Piper and A&L Goodbody advised Medtronic, while Davis Polk advised the representatives of the several underwriters. Medtronic Global Holdings S.C.A. issued $1 billion...

Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...

Davis Polk and Hogan Lovells advised Precigen on the offering, and Goodwin Procter advised the underwriters involved. Precigen Inc. announced the SEC-registered offering of an aggregate of...

Davis Polk advised Metalmark Capital on the deal. Metalmark Capital executed its investment of up to $50 million in Orgenesis’s U.S.-based point of care services subsidiary, Morgenesis...